Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

J&J uses FDA Priority Review Voucher to snag psoriasis approval

July 14, 2017
Medical Communications, Sales and Marketing Janssen, Johnson & Johnson, Tremfya, biotech, drugs, pharma, pharmaceutical

The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this …

News

Making strides in hepatitis

June 19, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson & Johnson

Pharmafocus caughtup with Lawrence Blatt, Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines, to discuss the progress being made in the …

Feature
janeg

J&J lines up its Global Head for Actelion

May 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, Janssen, Johnson & Johnson

The deal is not yet complete but the last steps are assumed to be a formality – at least Johnson …

Appointment

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

May 3, 2017
Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …

News
janssen_latest_logo_on_sign

Janssen scores EU approval for blood cancer drug Darzalex

May 2, 2017
Manufacturing and Production, Sales and Marketing Europe, European Commission, Janssen, darzalex

Janssen has announced that its CD38-directed monoclonal antibody Darzalex (daratumumab) has expanded its indication with a thumbs-up from the European …

News
janssen_latest_logo_on_sign

Janssen acquires over 90% of Actelion

April 24, 2017
Sales and Marketing Actelion, Janssen

Actelion has revealed that, following the wrap of its $30 billion deal in January, Janssen Holding has acquired 92.51% of …

News
janssen_latest_logo_on_sign_closer

Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

March 6, 2017
Research and Development, Sales and Marketing Humira, Janssen, guselkumab, psoriasis

Janssen has revealed new Phase 3 data for its human monoclonal antibody guselkumab in the treatment of adults with moderate …

News
janssen_latest_logo_on_sign_closer

EMA recommends expanded indication for Janssen multiple myeloma drug

February 27, 2017
Manufacturing and Production, Research and Development, Sales and Marketing Janssen, darzalex

The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its positive opinion for the use of …

News

Bayer’s cardiovascular drug races to target in trial

February 9, 2017
Research and Development, Sales and Marketing Bayer, Janssen, Xarelto

Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it …

News
imbruvica_logo_0

NICE approves Imbruvica for second-line leukaemia treatment

January 26, 2017
Medical Communications, Sales and Marketing AbbVie, CLL, Janssen, ibrutinib, imbruvica

NICE has issued its Technology Appraisal Guidance (TAG) that has recommend Imbruvica (ibrutinib) for the treatment of chronic lymphocytic leukaemia …

News
jj

J&J finally seals $30 billion deal for Actelion

January 26, 2017
Sales and Marketing Actelion, Janssen, Johnson & Johnson

Johnson & Johnson has, as expected, wrapped up the deal to acquire Actelion in a deal worth $30 billion, working …

News
janssen_latest_logo_on_sign_closer

SMC rejects Janssen’s multiple myeloma treatment Darzalex

January 17, 2017
Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex

The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …

News
mauriciof-269

Advancing the Pharmaceutical Supply Chain

January 13, 2017
Manufacturing and Production, Medical Communications Janssen, batch manufacturing, continuous manufacturing

Mauricio Futran, vice president, Process Sciences, Janssen Supply Chain, discusses, in the latest issue of Pharmafile, Janssen’s move into continuous …

News
shutterstock_92671375

Five major pharma firms break ABPI code of conduct, according to watchdog

December 15, 2016
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen

Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …

News
imbruv_pack

Janssen reveals positive results from longest follow-up of Imbruvica

December 7, 2016
Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica

Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025